Nanobiotix S.A. (NBTX) vs Tyra Biosciences (TYRA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Nanobiotix S.A. (NBTX) has outperformed Tyra Biosciences (TYRA) over the past year, gaining 26.6% versus a loss of 4.7%. Over five years, NBTX leads with a +214.0% price change compared with -15.7% for TYRA. Tyra Biosciences is the larger company by market cap ($1.39 billion vs $1.35 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NBTX | TYRA |
|---|---|---|
| Share price | $26.50 | $20.12 |
| Market cap | $1.35B | $1.39B |
| 1-day change | -2.98% | +1.98% |
| YTD return | +14.62% | -23.47% |
| 1-year return | +26.61% | -4.73% |
| 5-year return | +213.98% | -15.71% |
| EPS (TTM) | $-1.27 | $-2.63 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | — | $-119.95M |
| 52-week high | $57.14 | $40.65 |
| 52-week low | $19.14 | $18.25 |
| Distance from 52-week high | -53.62% | -50.50% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +101.06% | +135.83% |
| Average volume | 148.94K | 852.56K |
| Shares outstanding | 50.95M | 69.08M |
| Employees | 98 | 87 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NBTX has outperformed TYRA by 31.3 percentage points over the past year.
About Nanobiotix S.A.
NBTX stock →Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs.
Health Care · Biotechnology: Pharmaceutical Preparations · 98 employees
About Tyra Biosciences
TYRA stock →Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.
Health Care · Biotechnology: Pharmaceutical Preparations · 87 employees
NBTX vs TYRA FAQ
Which is bigger, Nanobiotix S.A. or Tyra Biosciences?
Tyra Biosciences (TYRA) is larger, with a market capitalization of $1.39B compared with $1.35B for Nanobiotix S.A. (NBTX).
Which stock has performed better over the past year, NBTX or TYRA?
NBTX returned +26.61% over the past 12 months, compared with -4.73% for TYRA (price return, excluding dividends). Past performance does not predict future results.
Are Nanobiotix S.A. and Tyra Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.